Pituitary Disease in Chronic Hepatitis C Infection and Interferon-alpha Related Therapy: Two Case Reports

Huy A Tran\textsuperscript{a, c, d}, Patricia A Crock\textsuperscript{b, c}, Glenn EM Reeves\textsuperscript{b, c}

Abstract

Pituitary dysfunction in chronic hepatitis C infection treated with interferon-α is a rare condition with 4 case reports worldwide. We hereby report two cases of pituitary dysfunction in HCV patients, with and without interferon-α therapy. Case 1: A 34-year-old man co-infected with HIV and HCV presented with a 3 month history of lethargy, listlessness and a general lack of energy. Past medical histories include inactive neurosyphilis, chronic schizophrenia and seizure. His HCV is genotype 1 without cirrhosis and he completed a 48-week course of combination IFN-α and RBV for 48 weeks uneventfully 3 months prior. Examination and investigation found him to isolated ACTH deficiency. His condition improved markedly with corticosteroid replacement therapy. Case 2: A 45-year-old and treatment naive man with chronic HCV infection presented with a 20 kg weight loss, lack of energy and the occasional dizziness. Examination and investigation found him to have panhypopituitarism. Replacement therapy was initiated including hydrocortisone, testosterone and hydrocortisone. He made a slow but steady recovery and regained about 15 kg of weight but unfortunately was lost to follow up. It concluded that hepatitis C infection on its own or in conjunction with interferon-α based therapy can result in pituitary failure. The condition is readily treatable and hence should be considered in the appropriate clinical setting.

Keywords: Pituitary; Hypophysitis; Hepatitis C; Interferon-alpha

Introduction

Pituitary pathology associated with interferon-α (IFN-α) therapy is an uncommon condition which so far has been poorly described and reported. Most are anecdotal with few unconvincing case reports. The mechanism as a result then is poorly understood but perhaps and similar to IFN-α related thyroid disease, immune-modulation is the major underlying pathogenesis. We hereby describe two cases of hepatitis C and IFN-α related disease where pituitary failure developed.

Case Report

Case 1

A 34-year-old man co-infected with Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) presented with a 3 month history of lethargy, listlessness and a general lack of energy. Past medical histories include treated and inactive neurosyphilis, chronic schizophrenia and seizure. His HCV is genotype 1 without cirrhosis and he completed a 48-week course of combination IFN-α and RBV for 48 weeks uneventfully 3 months prior.

Clinically he was unwell with BP of 110/70 sitting and 100/60 standing and PR of 89 beats per minute (bpm). General examination was unremarkable and there was no pigmentation. A baseline serum cortisol was 36 nmol/L at 07:05 hrs with Adrenocorticotropic (ACTH) level of 3.3 pmol/L (Reference Range (RR), < 10). His Thyrotropin (TSH) level was 0.96 mIU/L (RR, 0.4 - 4.0), free tetra-iodothyronine (FT4) of 19.1 pmol/L (RR, 10.8 - 21.0), Luteinising Hormone (LH) 13.8 IU/L (RR, 5.5 - 11.5), Follicular Stimulating Hormone (FSH) 7.7 IU/L (RR, 2.1 - 8.0), Testosterone 13.9 nmol/L (RR, 8.0 - 25.9), Growth Hormone (GH) < 0.2 mIU/L, Insulin-like Growth Factor 1 (IgF-1) 0.73 U/mL, Growth Hormone (GH) < 0.2 mIU/L, Insulin-like Growth Factor 1 (Igf-1) 0.73 U/mL (RR, 0.5 - 2.0), Proactin 402 mIU/L (RR, < 410). A 250 μg Synacthen stimulation test showed a rise from baseline of 70 to 304 nmol/L at 60 minutes. His electrolytes were normal with Na of 137 and K 4.1 mmol/L. His pituitary Magnetic Resonance Imaging was normal. Pituitary antibodies were...
The patient was started on Hydrocortisone with marked improvement. Mineralocorticoid replacement therapy was not indicated as this is likely to be secondary adrenal insufficiency. The patient was to be followed up for an assessment of possible pituitary recovery.

Case 2

A 45-year-old man presented with cachexia, unintentional 25 kg weight loss over 6 months, recurrent nausea and vomiting on a background of chronic hepatitis C infection which he had acquired 20 years before from intravenous drug use. His past medical history included type 2 diabetes which recently became labile. He also developed recurrent hypoglycaemia without any major changes in his routine dietary and oral intake. There was no change or non-compliance with his oral hypoglycaemic regimen. Clinically he was unwell, cachectic with weight of 56.2 kg and height of 1.65 m, body mass index of about 20 kg/m². His BP was 120/70 sitting and 100/60 standing with pulse rate of 88 bpm. He appeared hypo-androgenic with sparse body hair distribution and an absence of pubic and axillary hair. His testes were 6 and 8 mL in size bilaterally. Further investigations are as follow: TSH 1.58 mU/L, fT4 9.1 pmol/L, fT3 4.7 pmol/L, ACTH < 1.1 pmol/L, Cortisol 326 nmol/L, LH 0.6 IU/L, FSH 0.3 IU/L, Testosterone < 0.7 nmol/L, Prolactin 252 mIU/L. A short-synacthen test revealed a rise from 326 to 430 nmol/L over 60 minutes consistent a sub-optimal response. On the basis of these results, no dynamic stimulation test was warranted.

The patient was given triple replacement therapy including thyroxine, cortisone acetate and testosterone isocaproate (Sustanon) injections. He made a rapid recovery and great symptomatic improvement. His hypoglycaemic crises resolved. Indeed, he became hyperglycaemic. He gained about 5 kg and was referred for treatment consideration with IFN-α therapy. However, he did not return for review and was subsequently lost to follow up.

Discussion

These two cases highlight the immuno-modulating effects of the hepatitis C viral particles and IFN-α based therapy. The proposed hypothesis for the development of autoimmune hypophysitis in HCV infection and IFN-based therapy. IL-6: Interleukin-6; IFN: Interferon; MHC-II: major histocompatability complex-II; T₁; T helper.
Table 1. Summary of Our Cases and Available Published Reports, Please Note Case 3 Involved Hepatitis B Infection

<table>
<thead>
<tr>
<th>Authors and Year of publications</th>
<th>Gender:Age</th>
<th>Pituitary Antibody status</th>
<th>MRI findings</th>
<th>Treatment modality</th>
<th>Panhypopituitarism and therapy</th>
<th>Reversibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Sakane et al, 1995</td>
<td>F:44</td>
<td>YES: GH3 cell</td>
<td>Normal</td>
<td>IFN-α monotherapy for 3 months</td>
<td>Y: Hydrocortisone and Thyroxine</td>
<td>Yes, after 11 months</td>
</tr>
<tr>
<td>2. Concha et al, 2003</td>
<td>M:39</td>
<td>NO: Normal Human Pituitary Tissues</td>
<td>Normal</td>
<td>IFN-α and RBV for 1 year</td>
<td>Y: Testosterone and Growth hormone</td>
<td>No</td>
</tr>
<tr>
<td>3. Chan et al, 2004</td>
<td>F:30 (HBV infection)</td>
<td>Not done</td>
<td>Anterior pituitary cyst</td>
<td>IFN-α monotherapy for 3 years</td>
<td>Y: Hydrocortisone, Oestrogen and Thyroxine</td>
<td>No</td>
</tr>
<tr>
<td>4. Ridnoujo et al, 2006</td>
<td>F:54</td>
<td>Not done</td>
<td>Not done</td>
<td>IFN-α and RBV for 48 weeks</td>
<td>Y: No therapy</td>
<td>Yes, transient</td>
</tr>
<tr>
<td>5. Our case 1</td>
<td>M:34</td>
<td>Not available</td>
<td>Normal</td>
<td>IFN-α and RBV for 48 weeks</td>
<td>Y: Hydrocortisone</td>
<td>Unknown. Lost to follow up</td>
</tr>
<tr>
<td>6. Our case 2</td>
<td>M:45</td>
<td>Not available</td>
<td>Normal</td>
<td>Untreated</td>
<td>Y: Hydrocortisone, Testosterone and Thyroxine</td>
<td>No</td>
</tr>
</tbody>
</table>
activates $T_h^1$ and $T_h^2$ cytokine activities which lead to the development of autoimmunity. In addition, the $T$ helpers are further in turn regulated by $T$ regulator cells ($T_{reg}$). The latter function is dampened in the presence of IFN-α therapy, amplifying the PRL response, leading to the clinical expression of anterior pituitary deficiency [3]. The PRL hypothesis is probably more relevant in post-partum nursing mothers where hyperprolactinaemia predominates. However, only 50% of the discussed cases are females and none was breastfeeding. Genetic predisposition must play a part, as is the vascular supply. The anterior pituitary has an extensive vascular supply, exposing the pituitary cells to the HCV particles, IFN-α and associated antibodies, Figure 1. It remains unknown if the condition is reversible, especially once the virus has been terminated or cured with IFN-α therapy. The extermination of the HCV particles also reduces the stimulating effect helping the reversibility of the condition.

Previous published cases in the literature were sparse. The first case was described by Sakane et al [4] in 1995 in which the endocrinopathies developed 2 months (out of six) after stopping IFN therapy. This case was shown to have pituitary antibodies against GH3 cells, a rat pituitary tumor cell line that secretes growth hormone and prolactin. Fortunately, the condition was reversible. In 2003, Concha et al [5] reported a second similar case. The proposed panhypopituitarism was detected 1 year after the completion of treatment although there was no evidence of antipituitary antibodies. Chan et al [6] described a case of panhypopituitarism but in the presence of hepatitis B infection. The patient developed amenorrhea whilst on treatment and displayed permanent panhypopituitarism thereafter. Ridruejo et al [7] in 2006 reported a possible case of reversible or spontaneously recovered hypophysitis whilst on combination IFN and RBV therapy. The diagnosis was clinically based in all cases using the temporal relationship with treatment, pituitary hormonal profile, pituitary magnetic resonance imagings, all of which are normal or non-contributory, and the absence of thyroid and other autoimmune markers. Except for case 3, all demonstrated the typical sequence of deficiencies in autoimmune hypophysitis where ACTH is the first to be affected, followed by TSH and then LH/FSH [8]. Antipituitary antibodies are also not available in most case as these remain poorly defined and the test is not routinely available in practice [8]. Contrary to de novo cases, none developed headache and/or visual disturbance. These few published cases are summarized in Table 1.

In addition, INF-α can unmask previously undetected pituitary Sheehan’s syndrome or syndrome of inappropriate antidiuresis [9-11] which can be fatal if unrecognized. The prevalence of pituitary dysfunction in relation to hepatitis C infection and IFN-α therapy is poorly known and appears very rare. Our previous report in postmortem cases found no evidence of pituitary involvement in untreated HCV cases [12]. This is not surprising given the rarity of clinical panhypopituitarism in relation to HCV infection and suggests that the condition occurs in an ad hoc fashion, presumably in genetically susceptible individuals. Surveillance therefore is not recommended. However, the diagnosis of pituitary dysfunction, either partial or complete should be considered in HCV patients with the appropriate clinical symptomatology. Similarly and not evidence based, patients should be followed up to assess for reversibility of the condition.

**Conclusion**

Hepatitis C infection and IFN-α associated pituitary dysfunction is rare but should be considered in the appropriate clinical setting. The condition is readily treatable and is potentially reversible.

**Disclosure Statement**

All authors have no conflict of interests relevant to this work.

**References**